Whittier Trust Co. Grows Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Whittier Trust Co. boosted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 2.4% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 121,943 shares of the medical research company's stock after acquiring an additional 2,866 shares during the period. Whittier Trust Co. owned about 0.07% of IQVIA worth $21,498,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the stock. Brighton Jones LLC increased its position in IQVIA by 244.4% during the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company's stock worth $703,000 after purchasing an additional 2,537 shares during the last quarter. Independent Advisor Alliance boosted its stake in shares of IQVIA by 49.7% in the fourth quarter. Independent Advisor Alliance now owns 1,729 shares of the medical research company's stock valued at $340,000 after purchasing an additional 574 shares during the period. Commonwealth Equity Services LLC raised its holdings in IQVIA by 0.6% in the fourth quarter. Commonwealth Equity Services LLC now owns 26,104 shares of the medical research company's stock valued at $5,130,000 after acquiring an additional 157 shares in the last quarter. Choate Investment Advisors raised its holdings in IQVIA by 11.1% in the fourth quarter. Choate Investment Advisors now owns 1,022 shares of the medical research company's stock valued at $201,000 after acquiring an additional 102 shares in the last quarter. Finally, Cibc World Markets Corp raised its holdings in IQVIA by 15.0% in the fourth quarter. Cibc World Markets Corp now owns 27,629 shares of the medical research company's stock valued at $5,429,000 after acquiring an additional 3,604 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Truist Financial cut their price objective on shares of IQVIA from $263.00 to $216.00 and set a "buy" rating on the stock in a report on Thursday, April 10th. UBS Group cut their price objective on shares of IQVIA from $255.00 to $185.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Hsbc Global Res cut shares of IQVIA from a "strong-buy" rating to a "hold" rating in a report on Friday, April 25th. HSBC cut shares of IQVIA from a "buy" rating to a "hold" rating and cut their price objective for the stock from $260.00 to $160.00 in a report on Friday, April 25th. Finally, Citigroup reaffirmed a "neutral" rating on shares of IQVIA in a report on Thursday, May 22nd. Eight investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $222.45.

IQVIA Stock Performance

NYSE:IQV traded down $2.79 during midday trading on Friday, reaching $160.46. The stock had a trading volume of 1,382,317 shares, compared to its average volume of 1,669,303. The firm has a fifty day simple moving average of $152.66 and a two-hundred day simple moving average of $171.09. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $252.88. The company has a quick ratio of 0.82, a current ratio of 0.82 and a debt-to-equity ratio of 2.19. The stock has a market cap of $27.76 billion, a P/E ratio of 21.86, a P/E/G ratio of 1.76 and a beta of 1.30.

IQVIA (NYSE:IQV - Get Free Report) last issued its earnings results on Tuesday, May 6th. The medical research company reported $2.70 EPS for the quarter, topping the consensus estimate of $2.63 by $0.07. The company had revenue of $3.83 billion for the quarter, compared to analyst estimates of $3.77 billion. IQVIA had a net margin of 8.61% and a return on equity of 29.16%. The business's revenue was up 2.5% on a year-over-year basis. During the same period in the previous year, the firm earned $2.54 EPS. On average, equities analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.